Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (10081)	5/19/1999 5:06:00 AM
From: xomadog2	Read Replies (1) \| Respond to of 17367

Have read many recent posts. Murphy price target seems rather arbitrary. But,if Amgen can have a market capitalization of $33 billion from sales of close to $3 billion and sell at close to ten (10) times sales,and XOMA were to have an approved drug,for Neuprex,and somehow get it approved for use in Sepsis,among other indications,then there is a possibility of XOMA having sales that at the same multiple of ten times sales for a market cap that Amgen has, XOMA could easily exceed Murphys target and sell at $100+ even $200+ per share.There are currently 50 million shares outstanding and at $4 this equals a market cap of $200 million. At $40, XOMA would have a market cap of $2 billion and need $200 million in sales to justify thatmarket price extension. To get to $200 in price with a market cap of $10 billion the company would need to have at least $1 billion in sales. All of this with the standard K disclaimer. Dont rely on my caluculation or math I could be all wrong.!!XOMA may never get a grug approved!!THe FDA may never approve a drug for this company.They may never get sales of $1 Billion even if they get approval.XOMA may not get the drug approved for SEPSIS. MAKE your own decision and dont rely on my thoughts.